BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 31502115)

  • 1. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Matsumoto K; Tanaka M; Uranishi H; Masuta M; Nishida S; Shimizu S; Hayashi Y; Suzuki A; Nakamura M
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1097-1105. PubMed ID: 31502115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of non-steroidal anti-inflammatory drug use with encephalopathy development: An analysis using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) databases.
    Kawada K; Ishida T; Yoshioka T; Fukuda H; Hayashi T; Goda M; Ishizawa K
    Pharmazie; 2024 Jun; 79(6):118-123. PubMed ID: 38877682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of pregabalin-induced adverse events related to falls using the FDA adverse event reporting system and Japanese Adverse Drug Event Report databases.
    Mukai R; Hasegawa S; Umetsu R; Nakao S; Shimada K; Uranishi H; Masuta M; Suzuki H; Nishibata Y; Nakamura M
    J Clin Pharm Ther; 2019 Apr; 44(2):285-291. PubMed ID: 30569470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database.
    Shimada K; Hasegawa S; Nakao S; Mukai R; Sasaoka S; Ueda N; Kato Y; Abe J; Mori T; Yoshimura T; Kinosada Y; Nakamura M
    Int J Med Sci; 2019; 16(9):1295-1303. PubMed ID: 31588196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the Association of Hand-Foot Syndrome with Anticancer Drugs Using the US Food and Drug Administration Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) Databases].
    Sasaoka S; Matsui T; Abe J; Umetsu R; Kato Y; Ueda N; Hane Y; Motooka Y; Hatahira H; Kinosada Y; Nakamura M
    Yakugaku Zasshi; 2016; 136(3):507-15. PubMed ID: 26935094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of anticholinergic adverse effects using two large databases: The US Food and Drug Administration Adverse Event Reporting System database and the Japanese Adverse Drug Event Report database.
    Nagai J; Ishikawa Y
    PLoS One; 2021; 16(12):e0260980. PubMed ID: 34855908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Expression Time of Ganciclovir-Induced Adverse Events Using JADER and FAERS.
    Ando G; Taguchi K; Enoki Y; Yokoyama Y; Kizu J; Matsumoto K
    Biol Pharm Bull; 2019; 42(11):1799-1804. PubMed ID: 31685764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
    Ohyama K; Kawakami H; Inoue M
    Biol Pharm Bull; 2017; 40(5):616-620. PubMed ID: 28458346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Incidence and risk factors for ifosfamide-related encephalopathy in sarcoma patients].
    Stern N; Sakji I; Defachelles AS; Lervat C; Ryckewaert T; Marliot G; Peugniez C; Deplanque D; Penel N
    Bull Cancer; 2017 Mar; 104(3):208-212. PubMed ID: 27986268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of adverse drug events in patients with bipolar disorders using the Japanese Adverse Drug Event Report database.
    Uwai Y; Nabekura T
    Pharmazie; 2022 Sep; 77(7):255-261. PubMed ID: 36199180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Encephalopathy after high-dose Ifosfamide: a retrospective cohort study and review of the literature.
    Sweiss KI; Beri R; Shord SS
    Drug Saf; 2008; 31(11):989-96. PubMed ID: 18840018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system.
    Huang J; Jia Y; Sun S; Meng L
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):68. PubMed ID: 32938499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
    J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide-induced encephalopathy due to a novel formulation of ifosfamide.
    Filhon B; Lacarra B; Hervouet C; Jaffray M; Schneider P; Vannier JP
    Pediatr Blood Cancer; 2016 Feb; 63(2):372-3. PubMed ID: 26397980
    [No Abstract]   [Full Text] [Related]  

  • 18. Adverse event reports in patients taking psychiatric medication during pregnancy from spontaneous reports in Japan and the United States: an approach using latent class analysis.
    Anzai T; Takahashi K; Watanabe M; Mochizuki M; Murashima A
    BMC Psychiatry; 2020 Mar; 20(1):118. PubMed ID: 32164630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
    Szabatura AH; Cirrone F; Harris C; McDonnell AM; Feng Y; Voit D; Neuberg D; Butrynski J; Fisher DC
    J Oncol Pharm Pract; 2015 Jun; 21(3):188-93. PubMed ID: 24664476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide encephalopathy associated with chemotherapy for musculoskeletal sarcomas: incidence, severity, and risk factors.
    Tajino T; Kikuchi S; Yamada H; Takeda A; Konno S
    J Orthop Sci; 2010 Jan; 15(1):104-11. PubMed ID: 20151259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.